NEW YORK (GenomeWeb) – Tekmira Pharmaceuticals this week announced that it has received a $1.5 million milestone payment from ag-bio firm Monsanto under the terms of a technology-licensing deal.
Earlier this year, Monsanto signed a four-year deal picking up access to Tekmira's proprietary lipid-based RNAi delivery technology for use in agricultural applications. Shortly after the arrangement was announced, Tekmira received a $14.5 million milestone.
According to Tekmira, the latest payment was triggered by the achievement of undisclosed program developments.